Whalesbook
A Staged Shift to Schedule III
The U.S. Justice Department's order on April 22, 2026, to move certain marijuana products from Schedule I to Schedule III is a significant but carefully defined policy change. This reclassification applies to FDA-approved cannabis medications and products used by state-licensed medical programs. Importantly, it does not mean federal legalization for recreational use, which stays under Schedule I. The wider impact on the cannabis industry depends on the Drug Enforcement Administration's (DEA) administrative hearing, scheduled to start on June 29, 2026. This hearing will discuss broader rescheduling, and the step-by-step process adds complexity for investors and businesses seeking clearer rules.
Tax Cuts Boost Profits, MSOs See Stock Gains
The most immediate, clear benefit comes from removing Section 280E of the Internal Revenue Code for licensed medical operators. This rule had prevented businesses dealing with Schedule I substances from deducting normal operating expenses, leading to very high tax rates, sometimes over 70%. By moving to Schedule III, these companies can now deduct expenses, lowering their tax burden to the standard corporate rate of about 21%. This financial stability provides a cash boost, improving company finances and profits. Across the sector, cannabis ETFs like the AdvisorShares Pure US Cannabis ETF (MSOS) have shown strong one-year gains, with MSOS up 111%. However, its five-year performance shows a large drop of 87%. Other ETFs like YOLO and CNBS also show similar recent strong gains but significant long-term losses. Companies such as Green Thumb Industries (GTBIF), which previously reported net income of $114.15 million and a pre-change P/E of 15X, are positioned for faster profit growth. Curaleaf Holdings (CURLF) has already shown confidence by announcing an $83 million share buyback program, signaling strong cash flow potential.
Benefits Limited, Future Uncertain
While the tax relief is substantial, it mainly affects state-licensed medical operators and FDA-approved products. This creates a divided market where MSOs with strong medical programs are set to benefit more in the short term. Competitors focused only on recreational markets or those without the right licenses may not see the same immediate financial lift, showing an unequal spread of benefits across the sector. Historically, the cannabis sector has been highly volatile. Past studies suggested it was less volatile than broader market indices like the S&P 500, DJIA, and NASDAQ, implying potential diversification benefits but also significant risk. However, previous policy shifts, like an Executive Order in December 2025, saw little stock reaction, suggesting caution towards small changes. The current move, while financially impactful, still leaves major problems like federal banking access and interstate commerce largely unaddressed.
Regulatory Questions Remain Ahead of DEA Hearing
The immediate relief is balanced by the fact that broader rescheduling of marijuana, including recreational products, still awaits a June 2026 administrative hearing. This creates a significant period of uncertainty. The outcome of this hearing is uncertain and could face legal fights, particularly regarding the legal reasoning used for the initial order. Companies like Aurora Cannabis (ACB) and Canopy Growth (CGC), which have historically struggled with negative cash flow and operational inefficiencies, may find it harder to survive this long period of uncertainty. The current reclassification is a long way from full federal legalization, and penalties for possession and distribution still exist at the federal level, though with less harsh consequences than for Schedule I substances. Furthermore, some states have recently rolled back employment protections for medical marijuana users, highlighting the complex and varied rules. The limited scope of the current order has already led to some cannabis firm shares reversing early gains as investors examined the details of the reclassification.
DEA Hearing to Determine Industry's Future
The cannabis industry's future path now largely depends on the outcome of the June 2026 DEA hearing. A wider shift to Schedule III could further normalize the industry, potentially attracting more large investors and expanding research capabilities. However, the path forward involves navigating potential opposition and ensuring alignment across federal and state regulatory frameworks. The current policy development, while a substantial step for specific segments, merely sets the stage for a more transformative, but uncertain, regulatory landscape that could reshape the market over the next eighteen months.